Guest Editors
Prof. Palma Fedele
Email: minafedele@hotmail.com
Affiliation: Oncology Unit, Dario Camberlingo Hospital, ASL Brindisi, 72021, Italy.
Homepage:
Research Interests: breast cancer, translation research, lung cancer, oncology management
Dr. Alessandro Rizzo
Email: rizzo.alessandro179@gmail.com
Affiliation: Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, 70124, Italy.
Homepage:
Research Interests: breast cancer, prostate cancer, gastrointestinal cancer
Summary
Breast cancer care is rapidly evolving due to major advances in molecular biology, liquid biopsy technologies, antibody–drug conjugates, and immunotherapy. These innovations are reshaping therapeutic algorithms across early-stage and metastatic settings, enabling more precise risk stratification and treatment personalization. At the same time, increasing clinical complexity highlights the need for multidisciplinary approaches that integrate oncology, pathology, cardio-oncology, and digital tools.
This Special Issue aims to provide a focused collection of translational and clinical studies addressing how next-generation diagnostics and therapies can be effectively implemented in real-world practice. Topics of interest include: biomarkers of resistance (ESR1, HER2-low, PI3K/AKT pathway), ctDNA and minimal residual disease, tumor microenvironment, novel endocrine therapies and SERDs, ADCs, immunotherapy in TNBC, de-escalation/escalation strategies, multidisciplinary care models, cardio-oncology, et al.
The Special Issue welcomes original research, reviews, meta-analyses, and perspective articles. It aims to offer clinicians and researchers an updated and practical overview of key scientific and organizational advances driving the next generation of precision and multidisciplinary breast cancer treatment.
Keywords
Breast cancer, precision oncology, translational research, molecular biomarkers, ESR1 mutations, HER2-low, liquid biopsy, ctDNA, minimal residual disease, antibody–drug conjugates, endocrine resistance, SERDs, immunotherapy, triple-negative breast cancer, real-world evidence, multidisciplinary care, cardio-oncology, implementation science.
Login
Register
Submit a Paper
Propose a Special lssue